Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa | Zendy

Wright W. Nichols | Zendy; Gregory G. Stone | Zendy; Paul Newell | Zendy; Helen Broadhurst | Zendy; Angela Wardman | Zendy; M. Macpherson | Zendy; Katrina Yates | Zendy; Todd Riccobene | Zendy; Ian A. Critchley | Zendy; Shampa Das | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Author(s) -

Wright W. Nichols,

Gregory G. Stone,

Paul Newell,

Helen Broadhurst,

Angela Wardman,

M. Macpherson,

Katrina Yates,

Todd Riccobene,

Ian A. Critchley,

Shampa Das

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02590-17

Subject(s) - ceftazidime/avibactam , pseudomonas aeruginosa , ceftazidime , avibactam , enterobacteriaceae , pharmacodynamics , microbiology and biotechnology , pharmacokinetics , medicine , pharmacology , biology , bacteria , escherichia coli , biochemistry , genetics , gene

Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8 mg/liter) and resistant (MIC, >8 mg/liter). The key supportive data from pharmacokinetic/pharmacodynamic analyses, in vitro surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research